Findings from the primary analysis of the KAITLIN trial suggest that replacement of adjuvant taxane with trastuzumab emtansine (T-DM1) does not improve survival or safety for patients with HER2-positive early-stage breast cancer . However, both treatments demonstrated outstanding long-term invasive disease–free survival (iDFS) in a high-risk population. Study author Nadia Harbeck, MD, PhD, of the University of Munich, in Germany, and West German Study Group, presented these data during the ASCO20 Virtual Scientific Program.
HER2-positive early-stage breast cancer is a particularly aggressive, and neoadjuvant chemotherapy plus HER2-targeted therapy is the standard of care. Despite its efficacy, patients remain at increased risk of recurrence, mortality, and taxane-related toxicity, making it critical to optimize HER2-targeted treatment and determine who might benefit the most.
“In 2005, we were lucky to have one HER2-targeted therapy to combine wi...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Advanced breast cancer: locoregional therapy does not improve OS Next Article
Maintenance olaparib improves OS in relapsed ovarian cancer with BRCA1/2 mutation »
Table of Contents: ASCO 2020
COVID-19 & Telemedicine
Breast & Ovarian Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.